RxDoctor Payments Data

Almira Cann, MD

Ophthalmology · Pasadena, CANPI 1699748392

Payments from drug & device makers

$581in general payments, 2019–2025

Across 18 payments — averaging $32.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$179
  • Bausch & Lomb Americas Inc.$125
  • Sun Pharmaceutical Industries Inc.$51
  • Johnson & Johnson Surgical Vision, Inc.$51
  • AbbVie$42
  • Biotissue Holdings Inc.$40
  • plus $93 from 4 others

What the payments were for

  • Food & beverage$56397%
  • Gifts$173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$581 in reported general payments places this provider in the 35th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$144,391
Medicare patients
279
Services billed
1,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine25$20,644
VyzultaLatanoprostene Bunod46$20,334
Cyclosporine45$19,542
MieboPerfluorohexyloctane/Pf15$15,974
LumiganBimatoprost24$13,717
RhopressaNetarsudil Mesylate38$13,710
CombiganBrimonidine Tartrate/Timolol22$8,120
Alphagan PBrimonidine Tartrate13$2,850
Brimonidine Tartrate55$2,712
Latanoprost120$1,309
Prednisolone Acetate30$1,280
Pilocarpine Hcl16$1,013
Dorzolamide Hcl58$981
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$291
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha20$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$42$45,33184 claims
Bausch & Lomb Americas Inc.Vyzulta, Miebo$125$36,30861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →